|
C8ORF33 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62436730732907E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.11022302462516E-16 |
| Normal-vs-Stage2 |
3.665900000005E-05 |
| Normal-vs-Stage3 |
6.21724893790088E-15 |
| Normal-vs-Stage4 |
1.63291602461868E-12 |
| Stage1-vs-Stage2 |
6.210100E-02 |
| Stage1-vs-Stage3 |
5.579800E-01 |
| Stage1-vs-Stage4 |
7.921900E-02 |
| Stage2-vs-Stage3 |
3.780100E-02 |
| Stage2-vs-Stage4 |
6.576400E-03 |
| Stage3-vs-Stage4 |
3.051000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
1.55679999999103E-05 |
| Normal-vs-Asian |
3.98660005007656E-09 |
| Caucasian-vs-AfricanAmerican |
2.674200E-01 |
| Caucasian-vs-Asian |
2.594800E-01 |
| AfricanAmerican-vs-Asian |
8.242400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.07611705604904E-14 |
| Normal-vs-Female |
1.62436730732907E-12 |
| Male-vs-Female |
5.024600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62503344114384E-12 |
| Normal-vs-Age(41-60Yrs) |
3.88578058618805E-15 |
| Normal-vs-Age(61-80Yrs) |
5.31320543117886E-11 |
| Normal-vs-Age(81-100Yrs) |
1.440440E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.983000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.620390E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.992800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.905600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.287400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.983200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.61910000001853E-06 |
| Classical-VS-Follicular |
2.335800E-03 |
| Classical-VS-Other |
4.291400E-01 |
| Classical-VS-Normal |
1.6242562850266E-12 |
| Tall-VS-Follicular |
8.47879999543721E-09 |
| Tall-VS-Other |
5.712200E-01 |
| Tall-VS-Normal |
1.62436730732907E-12 |
| Follicular-VS-Other |
1.235980E-01 |
| Follicular-VS-Normal |
1.98719999999764E-05 |
| Other-VS-Normal |
1.190110E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.61799462716772E-11 |
| Normal-vs-N1 |
1.11022302462516E-16 |
| N0-vs-N1 |
4.175800E-04 |
|
|
